<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570739</url>
  </required_header>
  <id_info>
    <org_study_id>WEL-411</org_study_id>
    <secondary_id>IND 68,466</secondary_id>
    <nct_id>NCT00570739</nct_id>
  </id_info>
  <brief_title>Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.</brief_title>
  <official_title>Effects of Metformin HCl in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, as Initial Therapy in Drug naïve Subjects With Type 2 Diabetes Mellitus, and the Effects of Colesevelam HCl on the Lipid Profile in Subjects With Pre Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 16-week double-blind, placebo-controlled (for colesevelam hydrochloride (HCl))
      study in the type 2 diabetic subjects and pre-diabetic subjects. Diabetic participants will
      also be treated with open label, background,metformin HCl. Two-hundred sixty subjects with
      type 2 diabetes (T2DM) and 200 pre-diabetic subjects are planned to be be enrolled. Qualified
      subjects with T2DM will be randomized 1:1 to receive metformin HCl plus colesevelam HCl or
      metformin HCl plus placebo matching colesevelam HCl. Qualified pre-diabetic subjects will be
      randomized 1:1 to receive colesevelam HCl or matching placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change of Hemoglobin A1C (HbA1C) From Baseline to 16 Weeks When Given as Initial Therapy to Drug-naïve, Diabetic Subjects.</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks.</measure>
    <time_frame>Baseline to 4, 8, 12, and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</measure>
    <time_frame>Baseline to 4, 8, 12, and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</measure>
    <time_frame>Baseline to 4, 8, 12, and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting C-Peptide Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 Minute Post-Meal Glucose Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 Hour Post-Meal Glucose Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Hour Post-Meal Glucose Levels to in Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Hour Post-Meal Insulin Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Hour Post-Meal C-Peptide Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percent Change of Low Density Lipoprotein Cholesterol (LDL-C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Non-High Density Lipoprotein (Non-HDL) Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of High Density Lipoprotein Cholesterol(HDL-C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Total Cholesterol (TC) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Triglycerides (TG)When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Apolipoprotein A-1 (Apo A-1) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Apolipoprotein B (Apo B)When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Apolipoprotein C3 (Apo C3)When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Levels of Various Lipoprotein Particles When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Size of Various Lipoprotein Particles When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Calculated Total Triglycerides When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Calculated Very Low Density Lipoprotein Triglycerides When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
    <description>These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Calculated High Density Lipoprotein Cholesterol When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
    <description>These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Achieving HbA1c Goal of &lt;7.0% at Weeks 4, 8, 12, and 16 if Baseline HbA1c Was &gt; or = to 7.0% When Given to Drug-naïve, Diabetics</measure>
    <time_frame>Baseline to 4, 8, 12, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subject Achieving HbA1c Goal of &lt;6.5% at Weeks 4, 8, 12, and 16 When Given to Drug-naïve, Diabetic Subjects</measure>
    <time_frame>Baseline to 4, 8, 12 and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of &lt;100 mg/dL at Weeks 8, 16 When Given to Drug-naïve, Diabetic Subjects</measure>
    <time_frame>Baseline to Weeks 8, and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol Goal of &lt;70 mg/dL at Weeks 8, 16 When Given as to Drug-naïve, Diabetics</measure>
    <time_frame>Baseline to Weeks 8, and 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist-to-Hip Ratio When Given to Drug-Naive Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Glucose Area Under the Curve (0 to 120 Minutes) From the Baseline Glucose Tolerance Test (GTT) to the 16 Week GTT</measure>
    <time_frame>Baseline vs. 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Various Calculated Lipid Parameters When Given as Initial Therapy to Drug-naïve, Diabetic From Baseline to 16 Weeks Subjects</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
    <description>These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Achieving 2-Hr. Post Meal Glucose Goal of &lt;180 mg/dL When Given to Drug-naïve, Diabetic Subjects From Baseline to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Achieving Hs-C-Reactive Protein Goal of &lt;2.0 mg/L When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Low Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Non-High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein A-1 in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein B in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein CIII in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</measure>
    <time_frame>Baseline to 8, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Hs-C-Reactive Protein in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Particle Size of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Various Calculated Lipid Parameters in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
    <description>These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of HbA1c in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</measure>
    <time_frame>Baseline to 4, 8, 12, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Fasting Plasma Glucose in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</measure>
    <time_frame>Baseline to 4, 8, 12, and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of Fasting Insulin in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</measure>
    <time_frame>Baseline to 4, 8, 12, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Fasting C-peptide Levels in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Glucose Levels 30 Minutes Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Glucose Levels 1 Hour Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Glucose Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Insulin Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of C-Peptide Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of &lt;100 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects</measure>
    <time_frame>Baseline to 8, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of &lt;70 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects</measure>
    <time_frame>Baseline to 8, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist-to-Hip Ratio in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for Plasma Glucose From 0 to 120 Minutes During the Oral Glucose Tolerance Tests in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Achievement of &lt;140 mg/dL Plasma Glucose 2 Hours Post the Oral Glucose Tolerance Test in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was &gt;or= to 140 mg/dL From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Achievement of &lt;110 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was &gt; or = to 110 mg/dL From Baseline to 4, 8, 12, and 16 Weeks</measure>
    <time_frame>Baseline to 4, 8, 12, and 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Achievement of &lt;100 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was &gt; or = to 100 mg/dL From Baseline to 4, 8, 12 and 16 Weeks</measure>
    <time_frame>Baseline to 4, 8, 12 and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Achievement of &lt;140 mg/dL Plasma Glucose Post 2 Hour Glucose Tolerance Test and Fasting Plasma Glucose &lt;110 mg/dL in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Achievement of Hs-C-Reactive Protein &lt;2.0 mg/L in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was &gt; or = to 2.0 mg/L From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Meeting Type 2 Diabetes Criteria (Fasting Plasma Glucose &gt;or= to 126 mg/dL or Plasma Glucose &gt;or= to 200 mg/dL Post 2 Hr Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</measure>
    <time_frame>Baseline to 16 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">502</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Pre-diabetes</condition>
  <arm_group>
    <arm_group_label>Diabetic Participants: Metformin HCl+Placebo for Colesevelam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic participants: Metformin HCl + Colesevelam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-diabetic Participants: Colesevelam Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-diabetes Participants: Colesevelam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin HCl and Colesevelam Placebo</intervention_name>
    <description>One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks</description>
    <arm_group_label>Diabetic Participants: Metformin HCl+Placebo for Colesevelam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin HCl tablets and Colesevelam tablets</intervention_name>
    <description>One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks</description>
    <arm_group_label>Diabetic participants: Metformin HCl + Colesevelam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam placebo</intervention_name>
    <description>Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks</description>
    <arm_group_label>Pre-diabetic Participants: Colesevelam Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam</intervention_name>
    <description>Six colesevelam 625 mg tablets will be given once a day for 16 weeks.</description>
    <arm_group_label>Pre-diabetes Participants: Colesevelam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 79 years, inclusive.

          -  HbA1C in the range of greater than or equal to 6.5 percent to small than or equal to
             10.0 percent, to be enrolled in the T2DM cohort.

          -  2-hour post 75 g OGTT glucose levels in the range of:

               -  greater than or equal to 200 mg/dL to be enrolled in the T2DM cohort, or

               -  greater than or equal to 140 to 200 mg/dL to be enrolled in the pre-diabetes
                  cohort.

          -  FPG levels in the range of:

               -  greater than or equal to 126 mg/dL to be enrolled in the T2DM cohort, or

               -  greater than or equal to 110 to smaller than or equal to 125 mg/dL to be enrolled
                  in the pre-diabetes cohort.

          -  LDL-C levels greater than or equal to 100 mg/dL.

          -  Drug-naïve, defined as having never received treatment for T2DM or not having received
             antidiabetic drug therapy during the 3 months prior to screening visit.

          -  Previous diagnosis of:

               -  T2DM or prediabetes, to be enrolled in the respective cohorts, or

               -  CHD, CVD, and/or primary hypercholesterolemia + BMI greater than or equal to 25
                  mg/kg2 to be screened for T2DM or pre-diabetes.

          -  Understanding of the study procedures and agreement to participate in the study by
             giving written informed consent at screening visit.

          -  Women may be enrolled if all 3 of the following criteria (in addition to the above
             criteria)are met:

               -  They are not pregnant (women of childbearing potential must have a negative serum
                  pregnancy test [serum beta human chorionic gonadotropin )] at screening visit);

               -  They are not breast-feeding; and

               -  They do not plan to become pregnant during the study.

          -  In addition to all of the above criteria, women must also meet 1 of the following 3
             criteria to be enrolled:

               -  They have been post-menopausal for at least 1 year; or

               -  They are of childbearing potential and will practice 1 of the following methods
                  of birth control throughout the study: oral, injectable, or implantable hormonal
                  contraceptives; intrauterine device; diaphragm plus spermicide; or female condom
                  plus spermicide. Methods of contraception that are not acceptable are partner's
                  use of condoms or partner's vasectomy.

        Exclusion Criteria:

          -  History of type 1 diabetes and/or history of acute or chronic metabolic acidosis,
             including diabetic ketoacidosis.

          -  History of chronic (requiring daily for greater than 2 months) use of insulin therapy,
             except for the treatment of gestational diabetes.

          -  Current or prior (within the past 3 months) treatment with an oral antidiabetic drug.

          -  Current or prior (within the past 3 months) treatment with colesevelam HCl (WelChol),
             colestipol, colestimide, or cholestyramine.

          -  History of dysphagia, swallowing disorders, or intestinal motility disorder.

          -  Any serious disorder, including pulmonary, hepatic, gastrointestinal (including
             clinically significant malabsorption), uncontrolled endocrine/metabolic,
             hematologic/oncologic (within the last 5 years), neurologic, and psychiatric diseases,
             that would interfere with the conduct of the study or interpretation of the data.

          -  Acute coronary syndrome (eg, myocardial infarction or unstable angina), coronary
             intervention (coronary artery bypass graft or percutaneous transluminal coronary
             angioplasty or similar procedure), congestive heart failure (requiring pharmacological
             treatment), or transient ischemic attack within 3 months of screening visit.

          -  History of pancreatitis.

          -  History of acquired immune deficiency syndrome or human immunodeficiency virus.

          -  History of drug or alcohol abuse within the past 2 years.

          -  Hospitalization for any cause within 14 days prior to screening visit.

          -  History of an allergic or toxic response to colesevelam HCl or any of its components.

          -  Known hypersensitivity to metformin HCl.

          -  Serum TG greater than or equal to 500 mg/dL.

          -  Body mass index (BMI) greater than 40 kg/m2 .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Jones</last_name>
    <role>Study Director</role>
    <affiliation>DSI</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pocatello</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gary</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dundee</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kent</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barranquilla</city>
        <state>Atlántico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucaramanga</city>
        <state>Santander</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <state>Dadar</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durgapura</city>
        <state>Jaipur</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nasik</city>
        <state>Mahārāshtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Palmas</city>
        <state>Chihuahua</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delegacion</city>
        <state>Cuauhtemoc</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hermosillo</city>
        <state>Sonora</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>India</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2007</study_first_submitted>
  <study_first_submitted_qc>December 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2007</study_first_posted>
  <results_first_submitted>April 6, 2010</results_first_submitted>
  <results_first_submitted_qc>July 12, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2010</results_first_posted>
  <last_update_submitted>July 19, 2010</last_update_submitted>
  <last_update_submitted_qc>July 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Michael Jones, Sr. Director, Medical Affairs</name_title>
    <organization>Daiichi Sankyo, Inc.</organization>
  </responsible_party>
  <keyword>Colesevelam</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Pre-diabetes</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Two cohorts of participants, type 2 diabetics (T2DM) and pre-diabetics, were recruited from 07 Jan 2008 to 15 Dec 2008. The sites were located in Colombia, India, Mexico, and the USA. The sites included private physician offices, group practices, clinics, hospitals, institutes, and university centers.</recruitment_details>
      <pre_assignment_details>Due to the different metabolic nature of the two groups the &quot;Total&quot; column under Baseline Characteristics is populated with data for the diabetic group, except where the total could be obtained by just adding the number of participants. Please note: in the outcomes section, LOCF=Last Observation carried forward</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Type 2 Diabetes Group: Placebo + Metformin</title>
          <description>This group received 6 matching colesevalm placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. This treatment duration was 16 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
          <description>This group received 6 colevevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. This treatment duration was 16 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Pre-diabetic Group: Placebo</title>
          <description>This group was given 6 placebo tablets once a day. They matched the colesevelam tablets. This treatment duration was 16 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Pre-diabetic Group: Colesevelam</title>
          <description>This group was given 6 colesevelam tablets, 625mg, once a day. This treatment duration was 16 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="145"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="92"/>
                <participants group_id="P4" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Required restricted medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Type 2 Diabetes Group: Placebo + Metformin</title>
          <description>This group received 6 matching colesevalm placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. This treatment duration was 16 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
          <description>This group received 6 colevevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. This treatment duration was 16 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Pre-diabetic Group: Placebo</title>
          <description>This group received 6 colesevelam matching placebo tablets once per day for 16 weeks</description>
        </group>
        <group group_id="B4">
          <title>Pre-diabetic Group: Colesevelam</title>
          <description>This group received 6 colesevelam tablets, 625mg, once per day for 16 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="141"/>
            <count group_id="B2" value="145"/>
            <count group_id="B3" value="108"/>
            <count group_id="B4" value="108"/>
            <count group_id="B5" value="502"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="10.11"/>
                    <measurement group_id="B2" value="52.7" spread="11.46"/>
                    <measurement group_id="B3" value="55.7" spread="11.14"/>
                    <measurement group_id="B4" value="53.3" spread="12.27"/>
                    <measurement group_id="B5" value="53.3" spread="10.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previously diagnosed with neither diabetes nor pre-diabetes</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previously diagnosed with pre-diabetes</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="85"/>
                    <measurement group_id="B5" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previously diagnosed with type 2 diabetes</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.78" spread="4.44"/>
                    <measurement group_id="B2" value="30.58" spread="4.669"/>
                    <measurement group_id="B3" value="30.82" spread="4.18"/>
                    <measurement group_id="B4" value="30.93" spread="4.89"/>
                    <measurement group_id="B5" value="30.19" spread="4.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145.7" spread="37.54"/>
                    <measurement group_id="B2" value="153.4" spread="39.04"/>
                    <measurement group_id="B3" value="106.8" spread="14.80"/>
                    <measurement group_id="B4" value="104.1" spread="11.33"/>
                    <measurement group_id="B5" value="149.6" spread="38.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting insulin</title>
          <units>uIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.82" spread="8.44"/>
                    <measurement group_id="B2" value="13.86" spread="15.75"/>
                    <measurement group_id="B3" value="11.03" spread="5.55"/>
                    <measurement group_id="B4" value="13.12" spread="8.75"/>
                    <measurement group_id="B5" value="13.34" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose 2 hours after meal</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220.3" spread="58.68"/>
                    <measurement group_id="B2" value="234.7" spread="71.36"/>
                    <measurement group_id="B3" value="153.7" spread="39.81"/>
                    <measurement group_id="B4" value="153.7" spread="37.90"/>
                    <measurement group_id="B5" value="227.7" spread="65.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160.6" spread="10.64"/>
                    <measurement group_id="B2" value="162.3" spread="9.67"/>
                    <measurement group_id="B3" value="159.1" spread="9.95"/>
                    <measurement group_id="B4" value="160.8" spread="9.96"/>
                    <measurement group_id="B5" value="161.5" spread="10.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.53" spread="0.94"/>
                    <measurement group_id="B2" value="7.76" spread="1.04"/>
                    <measurement group_id="B3" value="6.07" spread="0.45"/>
                    <measurement group_id="B4" value="6.02" spread="0.46"/>
                    <measurement group_id="B5" value="7.65" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135.5" spread="26.66"/>
                    <measurement group_id="B2" value="129.1" spread="23.08"/>
                    <measurement group_id="B3" value="136.8" spread="28.48"/>
                    <measurement group_id="B4" value="132.8" spread="23.88"/>
                    <measurement group_id="B5" value="132.2" spread="25.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.26" spread="16.17"/>
                    <measurement group_id="B2" value="80.84" spread="15.53"/>
                    <measurement group_id="B3" value="78.18" spread="13.76"/>
                    <measurement group_id="B4" value="80.63" spread="18.02"/>
                    <measurement group_id="B5" value="79.08" spread="15.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks.</title>
        <time_frame>Baseline to 4, 8, 12, and 16 weeks</time_frame>
        <population>The number analyzed equals the full analysis set. The full analysis set included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. This analysis set was used for the summary and analysis of all efficacy variables. LOCF was not used.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group:Placebo+Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group:Colesevelam+Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks.</title>
          <population>The number analyzed equals the full analysis set. The full analysis set included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. This analysis set was used for the summary and analysis of all efficacy variables. LOCF was not used.</population>
          <units>Percentage of change in HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 4 weeks:Pla+Met, N=128, Col+Met N=129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.044"/>
                    <measurement group_id="O2" value="-0.53" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 8 weeks:Pla+Met, N=123, Col+Met N=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.055"/>
                    <measurement group_id="O2" value="-0.84" spread="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 weeks:Pla+Met, N=115, Col+Met N=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.062"/>
                    <measurement group_id="O2" value="-1.05" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 weeks:Pla+Met, N=118, Col+Met N=122</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="0.064"/>
                    <measurement group_id="O2" value="-1.17" spread="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 4 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0123</p_value>
            <p_value_desc>P-Value is for the LS mean difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0201</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0239</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0046</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</title>
        <time_frame>Baseline to 4, 8, 12, and 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo+Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group:Colesevelam+Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline to 4 weeks Pla+Met N=130, Col+Met N=131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.0" spread="2.31"/>
                    <measurement group_id="O2" value="-24.0" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline to 8 weeks:Pla+Met N=122, Col+Met N=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.3" spread="1.97"/>
                    <measurement group_id="O2" value="-27.6" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline to 12 weeks:Pla+Met N=121, Col+Met N=125</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.3" spread="2.21"/>
                    <measurement group_id="O2" value="-28.4" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline to 16 weeks:Pla+Met N=119, Col+Met N=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.0" spread="2.21"/>
                    <measurement group_id="O2" value="-30.5" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline to 16wks LOCF:Pla+Met N=137,Col+Met N=138</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.9" spread="2.19"/>
                    <measurement group_id="O2" value="-28.0" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 4 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1112</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.3</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2167</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.6</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7269</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.0</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4063</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 weeks (LOCF)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4909</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Insulin When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</title>
        <time_frame>Baseline to 4, 8, 12, and 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group:Placebo+Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group:Colesevelam+Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin When Given to Drug-naïve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>uIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 4 weeks:Pla+Met, N=127, Col+Met N=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.124" spread="0.7219"/>
                    <measurement group_id="O2" value="-2.427" spread="0.7219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 8 weeks:Pla+Met, N=124, Col+Met N=126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.992" spread="0.5407"/>
                    <measurement group_id="O2" value="-3.007" spread="0.5376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 weeks:Pla+Met, N=117, Col+Met N=123</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.204" spread="0.5159"/>
                    <measurement group_id="O2" value="-3.708" spread="0.5048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 weeks:Pla+Met, N=119, Col+Met N=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.978" spread="0.7379"/>
                    <measurement group_id="O2" value="-2.802" spread="0.7217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to16wks LOCF:Pla+Met,N=137,Col+Met N=138</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.847" spread="0.6655"/>
                    <measurement group_id="O2" value="-2.637" spread="0.6644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 4 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7606</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.303</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.259</ci_lower_limit>
            <ci_upper_limit>1.653</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1782</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.015</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.477</ci_lower_limit>
            <ci_upper_limit>0.447</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0332</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.504</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.887</ci_lower_limit>
            <ci_upper_limit>-0.121</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8610</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.176</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.805</ci_lower_limit>
            <ci_upper_limit>2.158</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 weeks (LOCF)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8196</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.210</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.599</ci_lower_limit>
            <ci_upper_limit>2.019</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting C-Peptide Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting C-Peptide Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.295" spread="0.0695"/>
                    <measurement group_id="O2" value="-0.449" spread="0.0683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16Wks LOCF Pla+Met N=133,Col+Met N=134</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.284" spread="0.0650"/>
                    <measurement group_id="O2" value="-0.426" spread="0.0644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1078</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.153</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.340</ci_lower_limit>
            <ci_upper_limit>0.034</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 weeks (LOCF)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1146</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.141</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.317</ci_lower_limit>
            <ci_upper_limit>0.035</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30 Minute Post-Meal Glucose Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>30 Minute Post-Meal Glucose Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.1" spread="3.46"/>
                    <measurement group_id="O2" value="-33.1" spread="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16Wks LOCF Pla+Met N=133,Col+Met N=132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.4" spread="3.44"/>
                    <measurement group_id="O2" value="-30.4" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9933</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>9.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8203</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.5</ci_lower_limit>
            <ci_upper_limit>8.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1 Hour Post-Meal Glucose Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>1 Hour Post-Meal Glucose Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.0" spread="3.91"/>
                    <measurement group_id="O2" value="-41.9" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF:N=131 Pla; N=129 Colesev</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.4" spread="3.92"/>
                    <measurement group_id="O2" value="-39.1" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1950</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.5</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1583</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.3</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2 Hour Post-Meal Glucose Levels to in Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>2 Hour Post-Meal Glucose Levels to in Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.0" spread="4.11"/>
                    <measurement group_id="O2" value="-38.14" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=129, Met N=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.4" spread="4.18"/>
                    <measurement group_id="O2" value="-36.2" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3663</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.1</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2524</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.9</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2 Hour Post-Meal Insulin Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>2 Hour Post-Meal Insulin Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.</population>
          <units>uIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.601" spread="3.2794"/>
                    <measurement group_id="O2" value="-10.551" spread="3.2370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=129, Met N=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.592" spread="3.4395"/>
                    <measurement group_id="O2" value="-10.156" spread="3.4399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8158</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.051</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.828</ci_lower_limit>
            <ci_upper_limit>9.929</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7433</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.565</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.966</ci_lower_limit>
            <ci_upper_limit>7.836</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2 Hour Post-Meal C-Peptide Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>2 Hour Post-Meal C-Peptide Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.317" spread="0.2424"/>
                    <measurement group_id="O2" value="-0.102" spread="0.2373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=129, Met N=130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.205" spread="0.2406"/>
                    <measurement group_id="O2" value="-0.135" spread="0.2374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5161</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.215</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.437</ci_lower_limit>
            <ci_upper_limit>0.867</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8319</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.070</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.581</ci_lower_limit>
            <ci_upper_limit>0.722</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percent Change of Low Density Lipoprotein Cholesterol (LDL-C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam+Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent Change of Low Density Lipoprotein Cholesterol (LDL-C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>percentage of change in LDL-C</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.83" spread="1.631"/>
                    <measurement group_id="O2" value="-24.01" spread="1.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=119, Met N=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.94" spread="1.852"/>
                    <measurement group_id="O2" value="-22.02" spread="1.813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=137, Met N=136</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.11" spread="1.695"/>
                    <measurement group_id="O2" value="-21.44" spread="1.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-18.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.61</ci_lower_limit>
            <ci_upper_limit>-13.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.09</ci_lower_limit>
            <ci_upper_limit>-12.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.96</ci_lower_limit>
            <ci_upper_limit>-11.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Non-High Density Lipoprotein (Non-HDL) Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Non-High Density Lipoprotein (Non-HDL) Levels When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>percentage of change in non-HDL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.79" spread="1.327"/>
                    <measurement group_id="O2" value="-18.19" spread="1.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=119, Met N=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.08" spread="1.460"/>
                    <measurement group_id="O2" value="-14.36" spread="1.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=137, Met N=136</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.38" spread="1.338"/>
                    <measurement group_id="O2" value="-13.70" spread="1.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.99</ci_lower_limit>
            <ci_upper_limit>-8.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.23</ci_lower_limit>
            <ci_upper_limit>-5.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Week LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.98</ci_lower_limit>
            <ci_upper_limit>-4.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of High Density Lipoprotein Cholesterol(HDL-C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of High Density Lipoprotein Cholesterol(HDL-C) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="1.506"/>
                    <measurement group_id="O2" value="5.61" spread="1.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=119, Met N=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.46" spread="1.277"/>
                    <measurement group_id="O2" value="8.78" spread="1.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=137, Met N=136</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.58" spread="1.160"/>
                    <measurement group_id="O2" value="8.39" spread="1.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2026</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>2.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.43</ci_lower_limit>
            <ci_upper_limit>6.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4506</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.12</ci_lower_limit>
            <ci_upper_limit>4.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2609</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>4.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Total Cholesterol (TC) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Total Cholesterol (TC) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change of TC</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.46" spread="1.009"/>
                    <measurement group_id="O2" value="-13.26" spread="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=119, Met=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.85" spread="1.217"/>
                    <measurement group_id="O2" value="-9.79" spread="1.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=137, Met=136</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.22" spread="1.115"/>
                    <measurement group_id="O2" value="-9.31" spread="1.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.53</ci_lower_limit>
            <ci_upper_limit>-6.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.23</ci_lower_limit>
            <ci_upper_limit>-3.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.14</ci_lower_limit>
            <ci_upper_limit>-3.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Triglycerides (TG)When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Triglycerides (TG)When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change of TG</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.39" lower_limit="-11.41" upper_limit="0.58"/>
                    <measurement group_id="O2" value="1.28" lower_limit="-4.48" upper_limit="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=119, Met N=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.12" lower_limit="-25.58" upper_limit="7.32"/>
                    <measurement group_id="O2" value="8.63" lower_limit="-8.74" upper_limit="36.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=137, Met N=136</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.55" lower_limit="-24.13" upper_limit="14.40"/>
                    <measurement group_id="O2" value="8.80" lower_limit="6.25" upper_limit="15.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0171</p_value>
            <p_value_desc>The P-Value was from the non-parametric ANCOVA stratified by country.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The median difference was calculated using Hodges-Lehmann point estimate and corresponding 95% CI was constructed using the method of Moses.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>13.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The P-Value was from the non-parametric ANCOVA stratified by country.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The median difference was calculated using Hodges-Lehmann point estimate and corresponding 95% CI was constructed using the method of Moses.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.66</ci_lower_limit>
            <ci_upper_limit>25.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The P-Value was from the non-parametric ANCOVA stratified by country.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The median difference was calculated using Hodges-Lehmann point estimate and corresponding 95% CI was constructed using the method of Moses.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.18</ci_lower_limit>
            <ci_upper_limit>25.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Apolipoprotein A-1 (Apo A-1) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Apolipoprotein A-1 (Apo A-1) When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change in Apo A-1</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="1.047"/>
                    <measurement group_id="O2" value="6.12" spread="1.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=113, Met N=120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" spread="1.052"/>
                    <measurement group_id="O2" value="8.51" spread="1.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=133, Met N=134</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="0.957"/>
                    <measurement group_id="O2" value="8.45" spread="0.953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0496</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>5.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0117</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>6.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.83</ci_lower_limit>
            <ci_upper_limit>7.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Apolipoprotein B (Apo B)When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Apolipoprotein B (Apo B)When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change in Apo B</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.59" spread="1.184"/>
                    <measurement group_id="O2" value="16.15" spread="1.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=113, Met N=120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.89" spread="1.340"/>
                    <measurement group_id="O2" value="-13.42" spread="1.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=133, Met N=134</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.20" spread="1.242"/>
                    <measurement group_id="O2" value="-12.17" spread="1.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.74</ci_lower_limit>
            <ci_upper_limit>-8.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.14</ci_lower_limit>
            <ci_upper_limit>-5.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.35</ci_lower_limit>
            <ci_upper_limit>-4.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Apolipoprotein C3 (Apo C3)When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Apolipoprotein C3 (Apo C3)When Given to Drug-naïve, Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change in Apo C3</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="2.527"/>
                    <measurement group_id="O2" value="12.58" spread="2.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=117, Met N=120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="2.932"/>
                    <measurement group_id="O2" value="18.58" spread="2.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=136, N=136</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.82" spread="2.621"/>
                    <measurement group_id="O2" value="17.89" spread="2.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.76</ci_lower_limit>
            <ci_upper_limit>19.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.64</ci_lower_limit>
            <ci_upper_limit>22.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.95</ci_lower_limit>
            <ci_upper_limit>22.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Levels of Various Lipoprotein Particles When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin for 16 Weeks</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin for 16 Weeks</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Type 2 Diabetes Group: Placebo + Metformin for 16 Weeks (LOCF)</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Type 2 Diabetes Group:Colesevelam+Metformin for 16 Weeks(LOCF)</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Levels of Various Lipoprotein Particles When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Very Low Density Lipoprotein (VLDL) Particle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.03" spread="2.361"/>
                    <measurement group_id="O2" value="2.81" spread="2.355"/>
                    <measurement group_id="O3" value="-3.71" spread="2.167"/>
                    <measurement group_id="O4" value="2.68" spread="2.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL Chylomicron Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.554"/>
                    <measurement group_id="O2" value="1.73" spread="0.552"/>
                    <measurement group_id="O3" value="-0.58" spread="0.507"/>
                    <measurement group_id="O4" value="1.76" spread="0.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium VLDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="1.496"/>
                    <measurement group_id="O2" value="4.84" spread="1.492"/>
                    <measurement group_id="O3" value="-2.28" spread="1.383"/>
                    <measurement group_id="O4" value="4.85" spread="1.396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small VLDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="1.536"/>
                    <measurement group_id="O2" value="-4.00" spread="1.532"/>
                    <measurement group_id="O3" value="-0.83" spread="1.413"/>
                    <measurement group_id="O4" value="-4.06" spread="1.426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Low Density Lipoprotein (LDL) Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-104.0" spread="27.04"/>
                    <measurement group_id="O2" value="-303.3" spread="27.05"/>
                    <measurement group_id="O3" value="-109.5" spread="25.49"/>
                    <measurement group_id="O4" value="-295.5" spread="25.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate Density Lipoprotein Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="4.24"/>
                    <measurement group_id="O2" value="-21.3" spread="4.24"/>
                    <measurement group_id="O3" value="-8.9" spread="4.03"/>
                    <measurement group_id="O4" value="-19.6" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large LDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" spread="15.74"/>
                    <measurement group_id="O2" value="-25.5" spread="15.69"/>
                    <measurement group_id="O3" value="45.1" spread="14.60"/>
                    <measurement group_id="O4" value="-24.2" spread="14.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small LDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-146.9" spread="31.63"/>
                    <measurement group_id="O2" value="-256.7" spread="31.63"/>
                    <measurement group_id="O3" value="-145.9" spread="29.52"/>
                    <measurement group_id="O4" value="-252.7" spread="29.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium Small LDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.0" spread="7.16"/>
                    <measurement group_id="O2" value="-48.2" spread="7.15"/>
                    <measurement group_id="O3" value="-30.8" spread="6.72"/>
                    <measurement group_id="O4" value="-46.2" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Small LDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-115.0" spread="24.96"/>
                    <measurement group_id="O2" value="-208.7" spread="24.97"/>
                    <measurement group_id="O3" value="-115.3" spread="23.31"/>
                    <measurement group_id="O4" value="-206.6" spread="23.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total High Density Lipoprotein (HDL) Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.352"/>
                    <measurement group_id="O2" value="2.41" spread="0.351"/>
                    <measurement group_id="O3" value="1.34" spread="0.332"/>
                    <measurement group_id="O4" value="2.35" spread="0.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large HDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.160"/>
                    <measurement group_id="O2" value="1.09" spread="0.161"/>
                    <measurement group_id="O3" value="0.55" spread="0.153"/>
                    <measurement group_id="O4" value="1.00" spread="0.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium HDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.275"/>
                    <measurement group_id="O2" value="0.50" spread="0.274"/>
                    <measurement group_id="O3" value="-0.26" spread="0.259"/>
                    <measurement group_id="O4" value="0.59" spread="0.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small HDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="0.385"/>
                    <measurement group_id="O2" value="0.74" spread="0.384"/>
                    <measurement group_id="O3" value="1.05" spread="0.362"/>
                    <measurement group_id="O4" value="0.70" spread="0.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Very Low Density Lipoprotein (VLDL) Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0363</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>13.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Total Very Low Density Lipoprotein (VLDL) Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0347</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>12.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>VLDL Chylomicron Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0028</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>3.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>VLDL Chylomicron Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>3.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medium VLDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.10</ci_lower_limit>
            <ci_upper_limit>11.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medium VLDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.35</ci_lower_limit>
            <ci_upper_limit>10.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Small VLDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1750</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.04</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Small VLDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1007</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.10</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Low Density Lipoprotein (LDL) Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-199.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-272.9</ci_lower_limit>
            <ci_upper_limit>-125.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Total Low Density Lipoprotein (LDL) Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-186.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-255.9</ci_lower_limit>
            <ci_upper_limit>-116.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intermediate Density Lipoprotein Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0466</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.3</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Intermediate Density Lipoprotein Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0570</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.8</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Large LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-77.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-120.3</ci_lower_limit>
            <ci_upper_limit>-35.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Large LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-69.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-109.2</ci_lower_limit>
            <ci_upper_limit>-29.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Small LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0124</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-109.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-195.8</ci_lower_limit>
            <ci_upper_limit>-23.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Small LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0098</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-106.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-187.6</ci_lower_limit>
            <ci_upper_limit>-26.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medium Small LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1020</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.6</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medium Small LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0997</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.8</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Very Small LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0069</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-93.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-161.6</ci_lower_limit>
            <ci_upper_limit>-25.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Very Small LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0052</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-91.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-155.2</ci_lower_limit>
            <ci_upper_limit>-27.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total High Density Lipoprotein (HDL) Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0524</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>1.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Total High Density Lipoprotein (HDL) Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0301</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Large HDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0416</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Large HDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0333</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medium HDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0693</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medium HDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0187</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Small HDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5765</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.34</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Small HDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4762</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment group</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Size of Various Lipoprotein Particles When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin for 16 Weeks</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin for 16 Weeks</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Type 2 Diabetes Group: Placebo + Metformin for 16 Weeks (LOCF)</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Type 2 Diabetes Group:Colesevelam+Metformin for 16 Weeks(LOCF)</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Size of Various Lipoprotein Particles When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>nm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Low Density Lipoprotein Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.868"/>
                    <measurement group_id="O2" value="1.41" spread="0.866"/>
                    <measurement group_id="O3" value="-1.02" spread="0.796"/>
                    <measurement group_id="O4" value="1.73" spread="0.804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Density Lipoprotein Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.053"/>
                    <measurement group_id="O2" value="0.15" spread="0.053"/>
                    <measurement group_id="O3" value="0.19" spread="0.049"/>
                    <measurement group_id="O4" value="0.15" spread="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Density Lipoprotein Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.023"/>
                    <measurement group_id="O2" value="0.17" spread="0.023"/>
                    <measurement group_id="O3" value="0.08" spread="0.021"/>
                    <measurement group_id="O4" value="0.17" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Very Low Density Lipoprotein Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0652</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>4.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Very Low Density Lipoprotein Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0137</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>4.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Low Density Lipoprotien Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4726</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Low Density Lipoprotein Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5715</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>High Density Lipoprotein Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0083</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>High Density Lipoprotein Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Calculated Total Triglycerides When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Calculated Total Triglycerides When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="6.44"/>
                    <measurement group_id="O2" value="17.6" spread="6.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=133, Met N=129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="5.88"/>
                    <measurement group_id="O2" value="18.2" spread="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0036</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>26.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.6</ci_lower_limit>
            <ci_upper_limit>43.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>27.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.2</ci_lower_limit>
            <ci_upper_limit>43.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Calculated Very Low Density Lipoprotein Triglycerides When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
        <description>These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.</description>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Calculated Very Low Density Lipoprotein Triglycerides When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
          <description>These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.</description>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.4" spread="6.36"/>
                    <measurement group_id="O2" value="22.4" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=133, Met N= 129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="5.81"/>
                    <measurement group_id="O2" value="22.9" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>29.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.5</ci_lower_limit>
            <ci_upper_limit>47.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>30.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.9</ci_lower_limit>
            <ci_upper_limit>46.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Calculated High Density Lipoprotein Cholesterol When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
        <description>These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.</description>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Calculated High Density Lipoprotein Cholesterol When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
          <description>These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.</description>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.62"/>
                    <measurement group_id="O2" value="5.8" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=133, Met N=129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.59"/>
                    <measurement group_id="O2" value="5.6" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0033</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change of Hemoglobin A1C (HbA1C) From Baseline to 16 Weeks When Given as Initial Therapy to Drug-naïve, Diabetic Subjects.</title>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>The number analyzed equals the full analysis set. The full analysis set included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. This analysis set was used for the summary and analysis of all efficacy variables. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Hemoglobin A1C (HbA1C) From Baseline to 16 Weeks When Given as Initial Therapy to Drug-naïve, Diabetic Subjects.</title>
          <population>The number analyzed equals the full analysis set. The full analysis set included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. This analysis set was used for the summary and analysis of all efficacy variables. LOCF was used.</population>
          <units>Percentage of change of hemoglobin A1C</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.064"/>
                    <measurement group_id="O2" value="-1.09" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0035</p_value>
            <p_value_desc>P-Value is for the LS mean difference between the treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects Achieving HbA1c Goal of &lt;7.0% at Weeks 4, 8, 12, and 16 if Baseline HbA1c Was &gt; or = to 7.0% When Given to Drug-naïve, Diabetics</title>
        <time_frame>Baseline to 4, 8, 12, and 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Achieving HbA1c Goal of &lt;7.0% at Weeks 4, 8, 12, and 16 if Baseline HbA1c Was &gt; or = to 7.0% When Given to Drug-naïve, Diabetics</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1"/>
                    <measurement group_id="O2" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 8 Weeks: Pla N=87, Met N=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 Weeks: Pla N=79, Met N=89</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5"/>
                    <measurement group_id="O2" value="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=83, Met N=87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                    <measurement group_id="O2" value="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=95, Met N=99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 4 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5848</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8147</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4957</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0467</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0589</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0049</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.38</ci_lower_limit>
            <ci_upper_limit>6.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0092</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>4.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subject Achieving HbA1c Goal of &lt;6.5% at Weeks 4, 8, 12, and 16 When Given to Drug-naïve, Diabetic Subjects</title>
        <time_frame>Baseline to 4, 8, 12 and 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subject Achieving HbA1c Goal of &lt;6.5% at Weeks 4, 8, 12, and 16 When Given to Drug-naïve, Diabetic Subjects</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percent of particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 8 Weeks: Pla N=118, Met N=121</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7"/>
                    <measurement group_id="O2" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 Weeks: Pla N=110, Met N=119</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=114, Met N=118</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                    <measurement group_id="O2" value="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=131, Met N=134</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                    <measurement group_id="O2" value="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 4 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Startified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0280</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0414</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0840</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0589</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0095</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>3.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0088</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>3.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of &lt;100 mg/dL at Weeks 8, 16 When Given to Drug-naïve, Diabetic Subjects</title>
        <time_frame>Baseline to Weeks 8, and 16</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of &lt;100 mg/dL at Weeks 8, 16 When Given to Drug-naïve, Diabetic Subjects</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2"/>
                    <measurement group_id="O2" value="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=114, Met N=116</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=131, Met N=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.78</ci_lower_limit>
            <ci_upper_limit>11.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.53</ci_lower_limit>
            <ci_upper_limit>9.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol Goal of &lt;70 mg/dL at Weeks 8, 16 When Given as to Drug-naïve, Diabetics</title>
        <time_frame>Baseline to Weeks 8, and 16</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol Goal of &lt;70 mg/dL at Weeks 8, 16 When Given as to Drug-naïve, Diabetics</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=119, Met N=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=1137, Met N=136</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0326</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0157</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by country</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0870</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>7.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00439</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>7.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>lb</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.11" spread="0.564"/>
                    <measurement group_id="O2" value="-4.91" spread="0.552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=134, Met N=134</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.71" spread="0.523"/>
                    <measurement group_id="O2" value="-4.56" spread="0.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7959</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.32</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8371</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist-to-Hip Ratio When Given to Drug-Naive Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist-to-Hip Ratio When Given to Drug-Naive Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0033" spread="0.00329"/>
                    <measurement group_id="O2" value="-0.0067" spread="0.00323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=134, Met N=134</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0030" spread="0.00306"/>
                    <measurement group_id="O2" value="-0.0065" spread="0.00304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4584</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0033</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0122</ci_lower_limit>
            <ci_upper_limit>0.0055</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4039</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0035</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0118</ci_lower_limit>
            <ci_upper_limit>0.0048</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed=the full analysis set (FAS). The FAS included randomized subjects who took at least 1 dose of randomized medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Last Observation Carried Forward was used for 16 week analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed=the full analysis set (FAS). The FAS included randomized subjects who took at least 1 dose of randomized medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Last Observation Carried Forward was used for 16 week analyses.</population>
          <units>Percentage of change in LDL-C</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="2.054"/>
                    <measurement group_id="O2" value="-13.89" spread="2.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.07</ci_lower_limit>
            <ci_upper_limit>-10.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Glucose Area Under the Curve (0 to 120 Minutes) From the Baseline Glucose Tolerance Test (GTT) to the 16 Week GTT</title>
        <time_frame>Baseline vs. 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Glucose Area Under the Curve (0 to 120 Minutes) From the Baseline Glucose Tolerance Test (GTT) to the 16 Week GTT</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>mg/dL*hr</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.10" spread="6.305"/>
                    <measurement group_id="O2" value="-77.56" spread="6.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=127, Met N=124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.34" spread="6.460"/>
                    <measurement group_id="O2" value="-71.88" spread="6.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2289</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.53</ci_lower_limit>
            <ci_upper_limit>6.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1997</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.22</ci_lower_limit>
            <ci_upper_limit>6.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Various Calculated Lipid Parameters When Given as Initial Therapy to Drug-naïve, Diabetic From Baseline to 16 Weeks Subjects</title>
        <description>These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.</description>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Type 2 Diabetes Group: Placebo + Metformin (LOCF)</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Type 2 Diabetes Group:Colesevelam+Metformin(LOCF)</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Various Calculated Lipid Parameters When Given as Initial Therapy to Drug-naïve, Diabetic From Baseline to 16 Weeks Subjects</title>
          <description>These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.</description>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calculated Total Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67"/>
                    <measurement group_id="O2" value="14.48"/>
                    <measurement group_id="O3" value="0.99"/>
                    <measurement group_id="O4" value="15.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calc.Very Low Density Lipoprotein Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.48"/>
                    <measurement group_id="O2" value="30.28"/>
                    <measurement group_id="O3" value="6.62"/>
                    <measurement group_id="O4" value="31.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calculated High Density Lipoprotein-Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.51"/>
                    <measurement group_id="O2" value="17.86"/>
                    <measurement group_id="O3" value="8.70"/>
                    <measurement group_id="O4" value="17.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Calculated Triglycerides</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0144</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.57</ci_lower_limit>
            <ci_upper_limit>23.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Calculated Triglycerides</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0037</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.63</ci_lower_limit>
            <ci_upper_limit>23.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Calculated Very Low Density Lipoprotein Triglycerides</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0060</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.59</ci_lower_limit>
            <ci_upper_limit>39.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Calculated Very Low Density Lipoprotein Triglycerides</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>24.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.71</ci_lower_limit>
            <ci_upper_limit>39.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Calculated High Density Lipoprotein-Cholesterol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.71</ci_lower_limit>
            <ci_upper_limit>13.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Calculated High Density Lipoprotein-Cholesterol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.27</ci_lower_limit>
            <ci_upper_limit>13.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects Achieving 2-Hr. Post Meal Glucose Goal of &lt;180 mg/dL When Given to Drug-naïve, Diabetic Subjects From Baseline to Week 16</title>
        <time_frame>Baseline to Week 16</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Achieving 2-Hr. Post Meal Glucose Goal of &lt;180 mg/dL When Given to Drug-naïve, Diabetic Subjects From Baseline to Week 16</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                    <measurement group_id="O2" value="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=95, Met N=97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9"/>
                    <measurement group_id="O2" value="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8804</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5525</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>2.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5648</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3170</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects Achieving Hs-C-Reactive Protein Goal of &lt;2.0 mg/L When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Type 2 Diabetes Group: Placebo + Metformin</title>
            <description>This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Achieving Hs-C-Reactive Protein Goal of &lt;2.0 mg/L When Given to Drug-naïve, Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=91, Met N=90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9008</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>4.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9035</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>3.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2874</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4344</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Low Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 Weeks</time_frame>
        <population>The No. analyzed=the full analysis set (FAS). The FAS included randomized subjects who took at least 1 dose of randomized medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The total treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg once daily. The total treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed=the full analysis set (FAS). The FAS included randomized subjects who took at least 1 dose of randomized medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables.</population>
          <units>Percentage of change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="1.888"/>
                    <measurement group_id="O2" value="-17.88" spread="1.921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=92, Col N=95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="2.191"/>
                    <measurement group_id="O2" value="-15.08" spread="2.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-19.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.61</ci_lower_limit>
            <ci_upper_limit>-14.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.24</ci_lower_limit>
            <ci_upper_limit>-11.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Non-High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Non-High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="1.433"/>
                    <measurement group_id="O2" value="-10.98" spread="1.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=92, Col N=95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="1.850"/>
                    <measurement group_id="O2" value="-9.08" spread="1.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=104, Col N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="1.739"/>
                    <measurement group_id="O2" value="-8.37" spread="1.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.26</ci_lower_limit>
            <ci_upper_limit>-8.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.15</ci_lower_limit>
            <ci_upper_limit>-5.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.69</ci_lower_limit>
            <ci_upper_limit>-4.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="1.398"/>
                    <measurement group_id="O2" value="2.85" spread="1.433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=92, Col N=95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.42" spread="1.580"/>
                    <measurement group_id="O2" value="3.57" spread="1.601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=104, Col N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="1.447"/>
                    <measurement group_id="O2" value="3.56" spread="1.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0357</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>7.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6878</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.01</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7972</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.37</ci_lower_limit>
            <ci_upper_limit>3.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="1.169"/>
                    <measurement group_id="O2" value="-8.15" spread="1.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=92, Col N=95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="1.519"/>
                    <measurement group_id="O2" value="-6.59" spread="1.536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=104, Col N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="1.422"/>
                    <measurement group_id="O2" value="-6.01" spread="1.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.02</ci_lower_limit>
            <ci_upper_limit>-5.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.25</ci_lower_limit>
            <ci_upper_limit>-4.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.03</ci_lower_limit>
            <ci_upper_limit>-3.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein A-1 in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein A-1 in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.032" spread="1.150"/>
                    <measurement group_id="O2" value="3.18" spread="1.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=89, Col N=94</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" spread="1.312"/>
                    <measurement group_id="O2" value="5.67" spread="1.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=102, Col N=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" spread="1.205"/>
                    <measurement group_id="O2" value="5.46" spread="1.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0257</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>6.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2238</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.32</ci_lower_limit>
            <ci_upper_limit>5.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2763</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.44</ci_lower_limit>
            <ci_upper_limit>4.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein B in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein B in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="1.435"/>
                    <measurement group_id="O2" value="-8.62" spread="1.487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=89, Col N=94</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="1.788"/>
                    <measurement group_id="O2" value="-8.00" spread="1.807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=102, Col N=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="1.648"/>
                    <measurement group_id="O2" value="-7.52" spread="1.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.68</ci_lower_limit>
            <ci_upper_limit>-5.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.40</ci_lower_limit>
            <ci_upper_limit>-3.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.50</ci_lower_limit>
            <ci_upper_limit>-3.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein CIII in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein CIII in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" spread="3.301"/>
                    <measurement group_id="O2" value="17.71" spread="3.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=88, Col N=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.31" spread="5.126"/>
                    <measurement group_id="O2" value="20.89" spread="5.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=100, Col N=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.38" spread="4.627"/>
                    <measurement group_id="O2" value="19.83" spread="4.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>13.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.87</ci_lower_limit>
            <ci_upper_limit>21.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0901</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.83</ci_lower_limit>
            <ci_upper_limit>24.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0918</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.71</ci_lower_limit>
            <ci_upper_limit>22.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
        <time_frame>Baseline to 8, and 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-6.95" upper_limit="7.69"/>
                    <measurement group_id="O2" value="16.57" lower_limit="4.94" upper_limit="25.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=92, Col N=95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.61" lower_limit="-10.46" upper_limit="5.21"/>
                    <measurement group_id="O2" value="5.91" lower_limit="-0.67" upper_limit="13.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=104, Col N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.35" lower_limit="-9.85" upper_limit="5.66"/>
                    <measurement group_id="O2" value="5.91" lower_limit="0.00" upper_limit="13.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>P-Value is from the non-parametric ANCOVA stratified by country</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Non-parametric</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>15.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.27</ci_lower_limit>
            <ci_upper_limit>25.83</ci_upper_limit>
            <estimate_desc>The median difference was calculated using Hodges-Lehmann point estimates and corresponding 95% confidence interval was constructed using the method of Moses.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>P-Value is from the non-parametric ANCOVA stratified by country</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Non-parametric</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>16.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.33</ci_lower_limit>
            <ci_upper_limit>26.02</ci_upper_limit>
            <estimate_desc>The median difference was calculated using Hodges-Lehmann point estimates and corresponding 95% confidence interval was constructed using the method of Moses.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <p_value_desc>P-Value is from the non-parametric ANCOVA stratified by country</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Non-parametric</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>14.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.11</ci_lower_limit>
            <ci_upper_limit>23.84</ci_upper_limit>
            <estimate_desc>The median difference was calculated using Hodges-Lehmann point estimates and corresponding 95% confidence interval was constructed using the method of Moses.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Hs-C-Reactive Protein in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Hs-C-Reactive Protein in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.04" lower_limit="-34.62" upper_limit="23.79"/>
                    <measurement group_id="O2" value="-13.43" lower_limit="-47.53" upper_limit="26.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to16 LOCF: Pla N=102, Col N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.24" lower_limit="-35.78" upper_limit="21.80"/>
                    <measurement group_id="O2" value="-14.12" lower_limit="-46.48" upper_limit="20.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6523</p_value>
            <p_value_desc>P-Value was from the non-parametric ANCOVA stratified by country</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Non-parametric</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-3.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.50</ci_lower_limit>
            <ci_upper_limit>10.32</ci_upper_limit>
            <estimate_desc>The median difference was calculated using Hodges-Lehmann point estimates and corresponding 95% confidence interval was constructed using the method of Moses.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3934</p_value>
            <p_value_desc>P-Value was from the non-parametric ANCOVA stratified by country</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Non-parametric</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-4.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.51</ci_lower_limit>
            <ci_upper_limit>8.77</ci_upper_limit>
            <estimate_desc>The median difference was calculated using Hodges-Lehmann point estimates and corresponding 95% confidence interval was constructed using the method of Moses.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Level of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. These 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pre-Diabetes Group: Placebo (LOCF)</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pre-Diabetes Group: Colesevelam (LOCF)</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. These 16 week analyses are both LOCF and no LOCF.</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Very Low Density Lipoprotein (VLDL) Particle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="3.363"/>
                    <measurement group_id="O2" value="1.92" spread="3.337"/>
                    <measurement group_id="O3" value="0.72" spread="3.132"/>
                    <measurement group_id="O4" value="2.25" spread="3.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large VLDL Chylomicron Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.80" spread="0.459"/>
                    <measurement group_id="O2" value="1.64" spread="0.453"/>
                    <measurement group_id="O3" value="-0.86" spread="0.424"/>
                    <measurement group_id="O4" value="1.53" spread="0.426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium VLDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="2.004"/>
                    <measurement group_id="O2" value="6.59" spread="1.986"/>
                    <measurement group_id="O3" value="1.15" spread="1.890"/>
                    <measurement group_id="O4" value="6.40" spread="1.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small VLDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="1.967"/>
                    <measurement group_id="O2" value="-6.34" spread="1.951"/>
                    <measurement group_id="O3" value="0.52" spread="1.837"/>
                    <measurement group_id="O4" value="-5.73" spread="1.844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Low Density Lipoprotein (LDL) Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="38.15"/>
                    <measurement group_id="O2" value="-135.2" spread="37.83"/>
                    <measurement group_id="O3" value="-25.7" spread="35.97"/>
                    <measurement group_id="O4" value="-138.4" spread="36.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate Density Lipoprotein (LDL) Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.9" spread="5.71"/>
                    <measurement group_id="O2" value="-15.3" spread="5.69"/>
                    <measurement group_id="O3" value="-14.7" spread="5.37"/>
                    <measurement group_id="O4" value="-17.0" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large LDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" spread="29.20"/>
                    <measurement group_id="O2" value="27.6" spread="28.99"/>
                    <measurement group_id="O3" value="91.3" spread="26.79"/>
                    <measurement group_id="O4" value="27.5" spread="26.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small LDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-110.9" spread="44.15"/>
                    <measurement group_id="O2" value="-148.6" spread="43.79"/>
                    <measurement group_id="O3" value="-102.5" spread="41.72"/>
                    <measurement group_id="O4" value="-149.4" spread="41.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium Small LDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.5" spread="9.02"/>
                    <measurement group_id="O2" value="-28.2" spread="8.95"/>
                    <measurement group_id="O3" value="-21.5" spread="8.48"/>
                    <measurement group_id="O4" value="-28.3" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Small LDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-78.3" spread="35.60"/>
                    <measurement group_id="O2" value="-120.3" spread="35.32"/>
                    <measurement group_id="O3" value="-81.0" spread="33.68"/>
                    <measurement group_id="O4" value="-121.0" spread="33.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total High Density Lipoprotein (HDL) Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.456"/>
                    <measurement group_id="O2" value="0.28" spread="0.452"/>
                    <measurement group_id="O3" value="0.38" spread="0.428"/>
                    <measurement group_id="O4" value="0.28" spread="0.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large HDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.211"/>
                    <measurement group_id="O2" value="1.09" spread="0.210"/>
                    <measurement group_id="O3" value="0.53" spread="0.197"/>
                    <measurement group_id="O4" value="1.10" spread="0.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium HDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.335"/>
                    <measurement group_id="O2" value="-0.03" spread="0.334"/>
                    <measurement group_id="O3" value="-0.24" spread="0.310"/>
                    <measurement group_id="O4" value="-0.05" spread="0.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small HDL Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.475"/>
                    <measurement group_id="O2" value="-0.77" spread="0.471"/>
                    <measurement group_id="O3" value="0.10" spread="0.450"/>
                    <measurement group_id="O4" value="-0.75" spread="0.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total VLDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9838</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.66</ci_lower_limit>
            <ci_upper_limit>8.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Total VLDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7157</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.73</ci_lower_limit>
            <ci_upper_limit>9.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Large VLDL Chylomicron Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>3.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Large VLDL Chylomicron Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>3.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medium VLDL Chylomicron Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0577</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>10.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medium VLDL Chylomicron Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0390</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>10.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Small VLDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0044</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.61</ci_lower_limit>
            <ci_upper_limit>-2.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Small VLDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0118</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.09</ci_lower_limit>
            <ci_upper_limit>-1.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Low Density Lipoprotein (LDL) Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0293</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-110.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-209.9</ci_lower_limit>
            <ci_upper_limit>-11.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Total Low Density Lipoprotein (LDL) Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0202</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-112.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-207.6</ci_lower_limit>
            <ci_upper_limit>-17.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intermediate Density Lipoprotein (LDL) Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9629</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.2</ci_lower_limit>
            <ci_upper_limit>14.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Intermediate Density Lipoprotein (LDL) Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7485</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.5</ci_lower_limit>
            <ci_upper_limit>11.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Large LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1007</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-63.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-139.7</ci_lower_limit>
            <ci_upper_limit>12.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Large LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0768</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-63.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-134.6</ci_lower_limit>
            <ci_upper_limit>6.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Small LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4143</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-47.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-162.7</ci_lower_limit>
            <ci_upper_limit>67.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Small LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4020</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-46.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-157.1</ci_lower_limit>
            <ci_upper_limit>63.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medium Small LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6378</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.1</ci_lower_limit>
            <ci_upper_limit>17.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medium Small LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5528</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.1</ci_lower_limit>
            <ci_upper_limit>15.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Very Small LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3730</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-42.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-134.8</ci_lower_limit>
            <ci_upper_limit>50.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Very Small LDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3764</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-40.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-129.0</ci_lower_limit>
            <ci_upper_limit>49.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total High Density Lipoprotein (HDL) Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9807</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.20</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Total High Density Lipoprotein (HDL) Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8615</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.23</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Large HDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0364</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Large HDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0340</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medium HDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6587</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Medium HDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6554</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Small HDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1957</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.06</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Small HDL Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1622</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.03</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Particle Size of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pre-Diabetes Group: Placebo (LOCF)</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pre-Diabetes Group: Colesevelam (LOCF)</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Particle Size of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>nm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Low Density Lipoprotein Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="0.956"/>
                    <measurement group_id="O2" value="4.15" spread="0.948"/>
                    <measurement group_id="O3" value="-1.43" spread="0.877"/>
                    <measurement group_id="O4" value="3.89" spread="0.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Density Lipoprotein Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".23" spread="0.068"/>
                    <measurement group_id="O2" value="0.11" spread="0.068"/>
                    <measurement group_id="O3" value="0.23" spread="0.064"/>
                    <measurement group_id="O4" value="0.12" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Density Lipoprotein Particles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.026"/>
                    <measurement group_id="O2" value="0.15" spread="0.026"/>
                    <measurement group_id="O3" value="0.05" spread="0.024"/>
                    <measurement group_id="O4" value="0.15" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Very Low Density Lipoprotein Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.51</ci_lower_limit>
            <ci_upper_limit>8.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Very Low Density Lipoprotein Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.00</ci_lower_limit>
            <ci_upper_limit>7.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Low Density Lipoprotein Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1742</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Low Density Lipoprotein Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1870</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>High Density Lipoprotein Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0063</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>High Density Lipoprotein Particles</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Various Calculated Lipid Parameters in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <description>These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.</description>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pre-Diabetes Group: Placebo (LOCF)</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pre-Diabetes Group: Colesevelam (LOCF)</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Various Calculated Lipid Parameters in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <description>These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.</description>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changes in Calculated Total Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="5.97"/>
                    <measurement group_id="O2" value="19.4" spread="5.91"/>
                    <measurement group_id="O3" value="-6.4" spread="5.60"/>
                    <measurement group_id="O4" value="18.0" spread="5.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes: Calculated Very Low Density Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="5.70"/>
                    <measurement group_id="O2" value="21.7" spread="5.64"/>
                    <measurement group_id="O3" value="-5.9" spread="5.34"/>
                    <measurement group_id="O4" value="20.6" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes in Calculated High Density Lipoprotein -C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.75"/>
                    <measurement group_id="O2" value="2.9" spread="0.74"/>
                    <measurement group_id="O3" value="1.4" spread="0.69"/>
                    <measurement group_id="O4" value="2.9" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes in Calculated Total Triglycerides</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>24.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.9</ci_lower_limit>
            <ci_upper_limit>39.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Changes in Calculated Total Triglycerides</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>24.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.6</ci_lower_limit>
            <ci_upper_limit>39.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes: Calculated Very Low Density Triglycerides</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>26.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.5</ci_lower_limit>
            <ci_upper_limit>41.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Changes: Calculated Very Low Density Triglycerides</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>26.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.5</ci_lower_limit>
            <ci_upper_limit>40.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes in Calculated High Density Lipoprotein-Cholesterol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1257</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Changes in Calculated High Density Lipoprotein-Cholesterol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1054</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of HbA1c in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</title>
        <time_frame>Baseline to 4, 8, 12, and 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of HbA1c in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.026"/>
                    <measurement group_id="O2" value="-0.09" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 8 weeks: Pla N=98, Col N=96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.026"/>
                    <measurement group_id="O2" value="-0.10" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 weeks: Pla N=94, Col N=94</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.026"/>
                    <measurement group_id="O2" value="-0.11" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 weeks: Pla N=90, Col N=95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.034"/>
                    <measurement group_id="O2" value="-0.11" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 weeks LOCF: Pla N=106, Col N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.030"/>
                    <measurement group_id="O2" value="-0.12" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 4 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2971</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2567</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1081</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0790</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0206</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Fasting Plasma Glucose in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</title>
        <time_frame>Baseline to 4, 8, 12, and 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Fasting Plasma Glucose in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.95"/>
                    <measurement group_id="O2" value="-3.5" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 8 weeks: Pla N=97, Col N=97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.94"/>
                    <measurement group_id="O2" value="-3.1" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 weeks: Pla N=95, Col N=95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.11"/>
                    <measurement group_id="O2" value="-2.4" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 weeks: Pla N=91, Col N=95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.87"/>
                    <measurement group_id="O2" value="-2.8" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 weeks LOCF: Pla N=106, Col N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.65"/>
                    <measurement group_id="O2" value="-3.1" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 4 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>-1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1184</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0615</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3617</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2372</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.0</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of Fasting Insulin in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</title>
        <time_frame>Baseline to 4, 8, 12, and 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of Fasting Insulin in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percentage of change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.269" spread="0.6651"/>
                    <measurement group_id="O2" value="-0.348" spread="0.6769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 8 Weeks: Pla N=94, Col N=97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.208" spread="0.4377"/>
                    <measurement group_id="O2" value="-0.513" spread="0.4377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 Weeks: Pla N=93, Col N=93</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.848" spread="0.4371"/>
                    <measurement group_id="O2" value="-2.066" spread="0.4463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=90, Col N=94</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.063" spread="1.2082"/>
                    <measurement group_id="O2" value="-0.497" spread="1.1980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=105, Col N=102</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="1.0597"/>
                    <measurement group_id="O2" value="-0.512" spread="1.0770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Baseline to 4 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2982</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.921</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.821</ci_lower_limit>
            <ci_upper_limit>2.663</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2361</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.695</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.458</ci_lower_limit>
            <ci_upper_limit>1.848</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0413</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.218</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.388</ci_lower_limit>
            <ci_upper_limit>-0.049</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7858</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.434</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.583</ci_lower_limit>
            <ci_upper_limit>2.715</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7314</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.493</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.321</ci_lower_limit>
            <ci_upper_limit>2.335</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Fasting C-peptide Levels in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Fasting C-peptide Levels in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" spread="0.1124"/>
                    <measurement group_id="O2" value="-0.050" spread="0.1132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=101, Col N=100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.049" spread="0.1041"/>
                    <measurement group_id="O2" value="-0.057" spread="0.1059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5530</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.089</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.385</ci_lower_limit>
            <ci_upper_limit>0.207</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4554</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.105</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.383</ci_lower_limit>
            <ci_upper_limit>0.172</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Glucose Levels 30 Minutes Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Glucose Levels 30 Minutes Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="3.82"/>
                    <measurement group_id="O2" value="-1.8" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=96, Col N=97</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="3.60"/>
                    <measurement group_id="O2" value="-2.5" spread="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8583</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.7</ci_lower_limit>
            <ci_upper_limit>8.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7975</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.5</ci_lower_limit>
            <ci_upper_limit>8.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Glucose Levels 1 Hour Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Glucose Levels 1 Hour Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="4.51"/>
                    <measurement group_id="O2" value="-8.0" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=93, Col N=98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="4.28"/>
                    <measurement group_id="O2" value="-8.6" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2330</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-18.5</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1412</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.2</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Glucose Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Glucose Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="4.65"/>
                    <measurement group_id="O2" value="-6.3" spread="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=98, Col N=98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="4.40"/>
                    <measurement group_id="O2" value="-6.1" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8192</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.7</ci_lower_limit>
            <ci_upper_limit>10.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7513</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.5</ci_lower_limit>
            <ci_upper_limit>9.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Insulin Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Insulin Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>uIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.563" spread="6.6122"/>
                    <measurement group_id="O2" value="-15.472" spread="6.4814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=92, Col N=94</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.784" spread="6.2865"/>
                    <measurement group_id="O2" value="-14.954" spread="6.2745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4301</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.910</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.156</ci_lower_limit>
            <ci_upper_limit>10.336</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5369</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.170</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.661</ci_lower_limit>
            <ci_upper_limit>11.321</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of C-Peptide Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of C-Peptide Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.447" spread="0.3527"/>
                    <measurement group_id="O2" value="-0.598" spread="0.3449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=93, Col N=96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.581" spread="0.3374"/>
                    <measurement group_id="O2" value="-0.551" spread="0.3359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7447</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.151</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.068</ci_lower_limit>
            <ci_upper_limit>0.765</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9476</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.029</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.853</ci_lower_limit>
            <ci_upper_limit>0.911</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of &lt;100 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects</title>
        <time_frame>Baseline to 8, and 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of &lt;100 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                    <measurement group_id="O2" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=88, Col N=86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=100, Col N=94</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.06</ci_lower_limit>
            <ci_upper_limit>13.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.89</ci_lower_limit>
            <ci_upper_limit>10.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of &lt;70 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects</title>
        <time_frame>Baseline to 8, and 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of &lt;70 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=92, Col N=95</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=104, Col N=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0104</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2224</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>9.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1990</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>9.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2778</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2785</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>lb</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.56" spread="0.823"/>
                    <measurement group_id="O2" value="-3.24" spread="0.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=103, Col N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.63" spread="0.758"/>
                    <measurement group_id="O2" value="-3.25" spread="0.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5353</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.84</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5475</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.64</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist-to-Hip Ratio in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist-to-Hip Ratio in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Change in Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0059" spread="0.00477"/>
                    <measurement group_id="O2" value="-0.0058" spread="0.00480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=103, Col N=101</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0051" spread="0.00437"/>
                    <measurement group_id="O2" value="-0.0061" spread="0.00447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0678</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0116</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0241</ci_lower_limit>
            <ci_upper_limit>0.0009</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0585</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0112</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0228</ci_lower_limit>
            <ci_upper_limit>0.0004</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve for Plasma Glucose From 0 to 120 Minutes During the Oral Glucose Tolerance Tests in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve for Plasma Glucose From 0 to 120 Minutes During the Oral Glucose Tolerance Tests in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>mg/dL*hr</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.26" spread="6.109"/>
                    <measurement group_id="O2" value="-8.27" spread="5.878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=92, Col N=96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.40" spread="5.791"/>
                    <measurement group_id="O2" value="-9.20" spread="5.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7051</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.64</ci_lower_limit>
            <ci_upper_limit>12.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5267</p_value>
            <p_value_desc>P-Value is for the LS Mean Difference between treatment groups</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.72</ci_lower_limit>
            <ci_upper_limit>10.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Achievement of &lt;140 mg/dL Plasma Glucose 2 Hours Post the Oral Glucose Tolerance Test in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was &gt;or= to 140 mg/dL From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Achievement of &lt;140 mg/dL Plasma Glucose 2 Hours Post the Oral Glucose Tolerance Test in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was &gt;or= to 140 mg/dL From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1"/>
                    <measurement group_id="O2" value="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=61, Col N=69</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5882</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7098</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6835</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8461</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Achievement of &lt;110 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was &gt; or = to 110 mg/dL From Baseline to 4, 8, 12, and 16 Weeks</title>
        <time_frame>Baseline to 4, 8, 12, and 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Achievement of &lt;110 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was &gt; or = to 110 mg/dL From Baseline to 4, 8, 12, and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="57.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 8 Weeks: Pla N=34, Col N=26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 Weeks: Pla N=34, Col N=26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9"/>
                    <measurement group_id="O2" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=32, Col N=25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3"/>
                    <measurement group_id="O2" value="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=36, Col N=29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 4 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2079</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4053</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5752</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7994</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9960</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>3.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7783</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9774</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Achievement of &lt;100 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was &gt; or = to 100 mg/dL From Baseline to 4, 8, 12 and 16 Weeks</title>
        <time_frame>Baseline to 4, 8, 12 and 16 weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Achievement of &lt;100 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was &gt; or = to 100 mg/dL From Baseline to 4, 8, 12 and 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 8 Weeks: Pla N=68, Col N=64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1"/>
                    <measurement group_id="O2" value="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 Weeks: Pla N=66, Col N=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks: Pla N=62, Col N=64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4"/>
                    <measurement group_id="O2" value="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=73, Col N=68</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                    <measurement group_id="O2" value="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 4 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 8 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4058</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 12 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0254</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1499</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>3.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0420</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>4.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2240</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0593</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Achievement of &lt;140 mg/dL Plasma Glucose Post 2 Hour Glucose Tolerance Test and Fasting Plasma Glucose &lt;110 mg/dL in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Achievement of &lt;140 mg/dL Plasma Glucose Post 2 Hour Glucose Tolerance Test and Fasting Plasma Glucose &lt;110 mg/dL in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9"/>
                    <measurement group_id="O2" value="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=69, Col N=75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2"/>
                    <measurement group_id="O2" value="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4794</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6667</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2768</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4395</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Achievement of Hs-C-Reactive Protein &lt;2.0 mg/L in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was &gt; or = to 2.0 mg/L From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Achievement of Hs-C-Reactive Protein &lt;2.0 mg/L in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was &gt; or = to 2.0 mg/L From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=78, Col N=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1375</p_value>
            <p_value_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>6.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1996</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>5.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0829</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to 16 Weeks LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1037</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Contained treatment and country as factors and baseline lab value as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects Meeting Type 2 Diabetes Criteria (Fasting Plasma Glucose &gt;or= to 126 mg/dL or Plasma Glucose &gt;or= to 200 mg/dL Post 2 Hr Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
        <time_frame>Baseline to 16 Weeks</time_frame>
        <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Diabetes Group: Placebo</title>
            <description>This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pre-Diabetes Group: Colesevelam</title>
            <description>This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Meeting Type 2 Diabetes Criteria (Fasting Plasma Glucose &gt;or= to 126 mg/dL or Plasma Glucose &gt;or= to 200 mg/dL Post 2 Hr Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks</title>
          <population>The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 16 Weeks LOCF: Pla N=87, Col N=84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the signing of the informed consent form until the end of the study + a follow up period (until the AE resolved or stabilized). This period of time equals about 17.5 weeks.</time_frame>
      <desc>AEs were noted by investigator or reported by subject. Nature, duration, remedial action, and severity of AE were recorded. Lab abnormalities were AEs if they needed intervention, further investigation, led to a change in medication, or were part of a larger disease process. Only 107 in the prediabetes colesevelam group because 1 did not take drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Type 2 Diabetes Group: Placebo + Metformin</title>
          <description>This group received 6 matching colesevalm placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. This treatment duration was 16 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Type 2 Diabetes Group: Colesevelam + Metformin</title>
          <description>This group received 6 colevevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. This treatment duration was 16 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Pre-diabetic Group: Placebo</title>
          <description>This group was given 6 placebo tablets once a day. They matched the colesevelam tablets. This treatment duration was 16 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Pre-diabetic Group: Colesevelam</title>
          <description>This group was given 6 colesevelam tablets, 625mg, once a day. This treatment duration was 16 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Polycystic Ovaries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Abdominal pain uppper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dyslipidemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The following language is employed: &quot;If identified by DSI, any of DSI's confidential information as defined herein shall be deleted...Nothing in this publication section shall be taken as giving DSI and right of editorial control over any publication prepared by the Study Site.&quot;</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Raia, Senior Director Professional Affairs</name_or_title>
      <organization>Daiichi Sankyo, Inc.</organization>
      <phone>(973) 944-2683</phone>
      <email>jraia@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

